Payment overview · 2025
General Payments
$169.44
5 reported records · 5 companies
Healthcare provider profile · identity verified
Anthony L. Cabreira, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LONGWOOD, FL · NPI 1619978095
Verified facts
What the public records show
CMS Open Payments records show Anthony L. Cabreira, M.D. received $169.44 in general payments during 2025 across 5 reported records.
Dexcom, Inc. accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $90.00 | 53.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.42 | 13.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.89 | 11.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.94 | 11.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.19 | 10.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $169.44 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $90.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 980 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 744 | 221 |
| Levothyroxine Sodium | Levothyroxine Sodium | 655 | 192 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 606 | 192 |
| Lisinopril | Lisinopril | 535 | 160 |
| Alprazolam | Alprazolam | 381 | 76 |
| Losartan Potassium | Losartan Potassium | 360 | 110 |
| Simvastatin | Simvastatin | 325 | 92 |
| Metformin Hcl | Metformin Hcl | 306 | 98 |
| Gabapentin | Gabapentin | 273 | 87 |
| Omeprazole | Omeprazole | 252 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 74 |
| Carvedilol | Carvedilol | 229 | 68 |
| Sertraline Hcl | Sertraline Hcl | 208 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 59 |
| Tramadol Hcl | Tramadol Hcl | 185 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 54 |
| Clonazepam | Clonazepam | 161 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 49 |
| Metformin Hcl Er | Metformin Hcl | 142 | 43 |
| Trazodone Hcl | Trazodone Hcl | 140 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 37 |
| Famotidine | Famotidine | 128 | 45 |
| Allopurinol | Allopurinol | 126 | 40 |
| Meloxicam | Meloxicam | 119 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 33 |
| Furosemide | Furosemide | 108 | 43 |
| Ezetimibe | Ezetimibe | 107 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 34 |
| Atenolol | Atenolol | 99 | 28 |
| Montelukast Sodium | Montelukast Sodium | 94 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 32 |
| Synthroid | Levothyroxine Sodium | 94 | 27 |
| Glipizide Er | Glipizide | 93 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 26 |
| Eliquis | Apixaban | 89 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 31 |
| Lorazepam | Lorazepam | 85 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 25 |
| Glipizide | Glipizide | 75 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 27 |
| Bupropion Xl | Bupropion Hcl | 68 | 22 |
| Jardiance | Empagliflozin | 67 | 17 |
| Methylprednisolone | Methylprednisolone | 67 | 57 |
| Celecoxib | Celecoxib | 66 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 20 |
| Azithromycin | Azithromycin | 64 | 59 |
| Valsartan | Valsartan | 63 | 19 |
| Methocarbamol | Methocarbamol | 61 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 61 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 19 |
| Fenofibrate | Fenofibrate | 55 | 17 |
| Potassium Chloride | Potassium Chloride | 54 | 15 |
| Farxiga | Dapagliflozin Propanediol | 52 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 17 |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 11 |
| Meclizine Hcl | Meclizine Hcl | 45 | 13 |
| Prednisone | Prednisone | 44 | 21 |
| Buspirone Hcl | Buspirone Hcl | 42 | 14 |
| Finasteride | Finasteride | 42 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 24 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | 11 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Clonidine Hcl | Clonidine Hcl | 21 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Indomethacin | Indomethacin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.44 · 5 records | Dexcom, Inc. | AREXVY, Dexcom G6 Transmitter, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error